CN119454720A - 用于治疗和预防艰难梭菌感染的方法 - Google Patents

用于治疗和预防艰难梭菌感染的方法 Download PDF

Info

Publication number
CN119454720A
CN119454720A CN202411540120.0A CN202411540120A CN119454720A CN 119454720 A CN119454720 A CN 119454720A CN 202411540120 A CN202411540120 A CN 202411540120A CN 119454720 A CN119454720 A CN 119454720A
Authority
CN
China
Prior art keywords
clostridium difficile
compound
subject
infection
difficile infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411540120.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·K·塔纳卡
M·P·德拉珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Spv2 Co ltd
Original Assignee
Paratek Spv2 Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Spv2 Co ltd filed Critical Paratek Spv2 Co ltd
Publication of CN119454720A publication Critical patent/CN119454720A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411540120.0A 2016-03-24 2017-03-24 用于治疗和预防艰难梭菌感染的方法 Pending CN119454720A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US62/312996 2016-03-24
US201662320053P 2016-04-08 2016-04-08
US62/320053 2016-04-08
CN201780032098.0A CN109152789A (zh) 2016-03-24 2017-03-24 用于治疗和预防艰难梭菌感染的方法
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780032098.0A Division CN109152789A (zh) 2016-03-24 2017-03-24 用于治疗和预防艰难梭菌感染的方法

Publications (1)

Publication Number Publication Date
CN119454720A true CN119454720A (zh) 2025-02-18

Family

ID=59900751

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411540120.0A Pending CN119454720A (zh) 2016-03-24 2017-03-24 用于治疗和预防艰难梭菌感染的方法
CN201780032098.0A Pending CN109152789A (zh) 2016-03-24 2017-03-24 用于治疗和预防艰难梭菌感染的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780032098.0A Pending CN109152789A (zh) 2016-03-24 2017-03-24 用于治疗和预防艰难梭菌感染的方法

Country Status (13)

Country Link
US (3) US20170319603A1 (enExample)
EP (1) EP3432891A4 (enExample)
JP (3) JP7458706B2 (enExample)
CN (2) CN119454720A (enExample)
AU (3) AU2017238644B2 (enExample)
BR (2) BR112018069303A2 (enExample)
CA (1) CA3018872A1 (enExample)
MX (2) MX2018011413A (enExample)
MY (1) MY197627A (enExample)
PH (1) PH12018502020A1 (enExample)
RU (1) RU2751509C1 (enExample)
SG (2) SG11201808246SA (enExample)
WO (1) WO2017165729A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
CN110087655A (zh) * 2016-11-01 2019-08-02 帕拉特克药品公司 9-氨基甲基米诺环素化合物及其在治疗社区获得性细菌性肺炎(cabp)中的用途
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
EP3846805A4 (en) * 2018-09-04 2022-08-24 Paratek Pharmaceuticals, Inc. Methods of treating mycobacterial infections using tetracycline compounds
CN112823014A (zh) * 2018-10-10 2021-05-18 营养株式会社 艰难梭菌感染的预防和/或治疗剂
AU2021288202A1 (en) * 2020-06-11 2022-12-08 Paratek Pharmaceuticals Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113614A1 (en) * 1991-07-24 1993-02-04 Scott Donald Whalen Antimicrobial treatment methods and compositions
MXPA03000055A (es) * 2000-07-07 2003-07-14 Tufts College Compuestos de monociclina sustituidos en posicion 9..
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332546A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
JP2009521456A (ja) * 2005-12-22 2009-06-04 ワイス チゲサイクリンでの胃腸管感染症の治療法
EP1991236A2 (en) * 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202021946A (zh) * 2008-05-19 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
AU2010213773B2 (en) * 2009-02-11 2014-07-17 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
KR102222273B1 (ko) * 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection

Also Published As

Publication number Publication date
EP3432891A4 (en) 2019-10-30
US20250049819A1 (en) 2025-02-13
WO2017165729A1 (en) 2017-09-28
EP3432891A1 (en) 2019-01-30
SG10201913559VA (en) 2020-02-27
US20170319603A1 (en) 2017-11-09
JP2019509318A (ja) 2019-04-04
CA3018872A1 (en) 2017-09-28
JP2024023187A (ja) 2024-02-21
MY197627A (en) 2023-06-29
PH12018502020A1 (en) 2019-07-15
SG11201808246SA (en) 2018-10-30
CN109152789A (zh) 2019-01-04
JP7458706B2 (ja) 2024-04-01
BR112018069303A2 (pt) 2019-01-22
US20200281948A1 (en) 2020-09-10
AU2025202020A1 (en) 2025-04-10
AU2023200798A1 (en) 2023-03-09
JP2022115985A (ja) 2022-08-09
MX2018011413A (es) 2019-01-10
AU2017238644B2 (en) 2022-12-15
BR122024000249A2 (pt) 2024-02-27
RU2751509C1 (ru) 2021-07-14
AU2017238644A1 (en) 2018-10-25
MX2023004969A (es) 2023-05-24

Similar Documents

Publication Publication Date Title
US20250049819A1 (en) Methods for treating and preventing c. difficile infection
US8097247B2 (en) Probiotic, lactic acid-producing bacteria and uses thereof
RU2412241C2 (ru) Способ профилактики желудочно- кишечных заболеваний у животных или людей, способ лечения желудочно-кишечных заболеваний у животных или людей и лекарственное средство для лечения или профилактики желудочно-кишечных заболеваний у животных или людей
Manga et al. Evaluation of changes induced in the probiotic Escherichia coli M17 following recurrent exposure to antimicrobials
Mathias et al. Management of adult Clostridium difficile digestive contaminations: a literature review
US20220054558A1 (en) Compositions comprising bacterial strains
Jamal et al. The influence of exposure to various concentrations of five antimicrobial agents on intracellular cytotoxin B production in Clostridioides difficile
RU2822455C1 (ru) Штамм Lactobacillus salivarius ВКШМ-Г-08ПД
Thenmozhi et al. FOOD BORNE PATHOGENS AND ITS PATHOPHYSIOLOGY
JP2001524523A (ja) 出血性大腸菌感染治療剤の製造のためのビコザマイシンの使用
Connor et al. Clostridium and The Ageing Gut
Chen Novel therapeutic approaches targeting Clostridium difficile
Estrada-Garcia et al. Foodborne Infections and Intoxications: Chapter 8. Escherichia coli

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination